Voyager Therapeutics, Inc.

United States of America


 
Total IP 230
Total IP Rank # 5,594
IP Activity Score 3.1/5.0    214
IP Activity Rank # 3,255
Stock Symbol
ISIN US92915B1061
Market Cap. 352M  (USD)
Industry Biotechnology
Sector Healthcare
Dominant Nice Class Scientific, technological and in...

Patents

Trademarks

85 9
26 1
103 2
4
 
Last Patent 2024 - Compositions and methods for tre...
First Patent 2015 - Chimeric capsids
Last Trademark 2024 - VOYAGER
First Trademark 2013 - VOYAGER THERAPEUTICS

Industry (Nice Classification)

Latest Inventions, Goods, Services

2024 Invention Aav capsid variants and uses thereof. The disclosure relates to compositions and methods for the...
Invention Tau binding compounds. The present disclosure provides anti-tau antibodies and vectorization the...
G/S Biological preparations for gene therapy; adeno-associated virus (aav) gene therapy preparations ...
G/S Biological preparations for gene therapy; adeno-associated virus (aav) gene therapy preparations...
Invention Compositions and methods for the treatment of tau-related disorders. The disclosure provides comp...
Invention Aav capsid variants and uses thereof. The disclosure relates to compositions and methods for the ...
Invention Compositions and methods for the treatment of disorders related to dystrophia myotonica protein k...
Invention Compositions and methods for the treatment of disorders related to frataxin deficiency. inter ali...
Invention Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 defi...
Invention Compositions and methods for the treatment of disorders related to cdkl5 deficiency. e.g.e.g., en...
Invention Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 def...
Invention Compositions and methods for the treatment of disorders related to ataxin-2. e.g.e.g., reducing o...
Invention Compositions and methods for regulating mapt. The disclosure relates to small interfering RNA (si...
Invention Compositions and methods for treating amyotrophic lateral sclerosis. The present disclosure relat...
Invention Aadc polynucleotides for the treatment of parkinson's disease. The disclosure relates to composi...
Invention Compositions and methods for treating huntington's disease. The present invention relates to sma...
G/S Biological preparations for gene therapy; adeno-associated virus (AAY) gene therapy preparations...
Invention Treatment of amyotrophic lateral sclerosis (als). The present disclosure relates to AAVs encodin...
Invention Baculovirus expression system. The disclosure provides variant viral genomes, e.g., variant bacul...
2023 Invention Central nervous system targeting polynucleotides. The present disclosure relates to compositions...
Invention Aav capsids with increased tropism to brain tissue. The disclosure relates to compositions, meth...
Invention Tau binding compounds. The present disclosure provides anti-tau antibodies and vectorization ther...
Invention Controlled expression of viral proteins. Spodoptera frugiperda Spodoptera frugiperda insect cells...
G/S Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations ...
Invention Compositions and methods for crossing the blood brain barrier. The disclosure relates to composit...
Invention Compositions and methods of treating huntington's disease. The present invention relates to aden...
Invention Tau binding compounds. The present disclosure provides anti-tau antibodies and adeno-associated v...
Invention Compositions and methods for the treatment of spinal muscular atrophy related disorders. The disc...
Invention Compositions and methods for the treatment of her2 positive cancer. The disclosure provides compo...
Invention Compositions and methods of treating amyotrophic lateral sclerosis (als). The present invention ...
Invention Compositions and methods for the treatment of neurological disorders related to glucosylceramidas...
Invention Baculovirus expression system.
2022 Invention Compositions and methods of treating amyotrophic lateral sclerosis (als). The present invention r...
Invention Compositions and methods for delivery of aav. The invention provides compositions and methods fo...
Invention Treatment of amyotrophic lateral sclerosis (als). The present invention relates to AAVs encoding ...
Invention Controlled expression of viral proteins. The present disclosure describes methods and systems fo...
G/S Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy; Biological p...
2021 Invention Tau binding compounds. The present disclosure provides anti-tau antibodies. Also provided are me...
Invention Compositions and methods for the treatment of tauopathy. The disclosure provides compositions an...
G/S Biotechnology research services; research and development of platform technologies for genetic de...
Invention Cell culture medium for use in producing gene therapy products in bioreactors. The present discl...
Invention Compositions and methods for the treatment of niemann-pick type c1 disease. The disclosure provi...
Invention Redirection of tropism of aav capsids. The disclosure relates to compositions, methods, and proc...
G/S Biological preparations for gene therapy; Biological preparations for treatment of neurological d...
G/S Biological preparations for gene therapy, namely, the treatment of Huntington's disease, Gaucher ...
Invention Methods and systems for producing aav particles. The present disclosure describes methods and sy...
2020 Invention Compositions and methods for the vectored augmentation of protein destruction, expression and/or ...
2018 G/S Medical system comprised of a surgical device for guiding, locating or placing a diagnostic devic...
2014 G/S Pharmaceutical research and development in the field of gene therapy